CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

PURPOSE: Patients with B-cell acute lymphoblastic leukemia who experience relapse after or are resistant to CD19-targeted immunotherapies have limited treatment options. Targeting CD22, an alternative B-cell antigen, represents an alternate strategy. We report outcomes on the largest patient cohort...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: Shah, Nirali N., Highfill, Steven L., Shalabi, Haneen, Yates, Bonnie, Jin, Jianjian, Wolters, Pamela L., Ombrello, Amanda, Steinberg, Seth M., Martin, Staci, Delbrook, Cindy, Hoffman, Leah, Little, Lauren, Ponduri, Anusha, Qin, Haiying, Qureshi, Haris, Dulau-Florea, Alina, Salem, Dalia, Wang, Hao-Wei, Yuan, Constance, Stetler-Stevenson, Maryalice, Panch, Sandhya, Tran, Minh, Mackall, Crystal L., Stroncek, David F., Fry, Terry J.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2020
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280047/
https://ncbi.nlm.nih.gov/pubmed/32286905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03279
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker